Anthrax vaccine
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Anthrax vaccine
- Accession Number
- DB11003
- Description
Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in at high risk of, suspected or confirmed exposure to Bacillus anthracis. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium [FDA Label].
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Other vaccines - Synonyms
- Anthrax vaccine adsorbed
- Bacillus anthracis inactivated antigen
- Bacillus anthracis strain V770-NP1-R antigen
- Bacillus anthracis strain V770-NP1-R antigens
- Bacillus anthracis strain V770-NP1-R filtrate (attenuated) antigen
- Bacillus anthracis strain V770-NP1-R filtrate antigen
- External IDs
- RPA102
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
- Not Available
- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Abacavir. Abatacept The risk or severity of infection can be increased when Anthrax vaccine is combined with Abatacept. Acyclovir The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Acyclovir. Adalimumab The risk or severity of infection can be increased when Anthrax vaccine is combined with Adalimumab. Adefovir dipivoxil The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Adefovir dipivoxil. Aldesleukin The risk or severity of infection can be increased when Anthrax vaccine is combined with Aldesleukin. Alefacept The risk or severity of infection can be increased when Anthrax vaccine is combined with Alefacept. Alemtuzumab The risk or severity of infection can be increased when Anthrax vaccine is combined with Alemtuzumab. Altretamine The risk or severity of infection can be increased when Anthrax vaccine is combined with Altretamine. Amantadine The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Amantadine. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image BioThrax Suspension 50 mcg Intramuscular; Subcutaneous Emergent Biodefense Operations Lansing Llc Not applicable Not applicable Canada 
BioThrax Injection, suspension 100 ug/1mL Intramuscular; Subcutaneous Emergent BioDefense Operations Lansing, LLC 1970-11-04 Not applicable US 
Categories
- Drug Categories
- Classification
- Not classified
Chemical Identifiers
- UNII
- 873OI62848
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347911075
- 404774
- Wikipedia
- Anthrax_vaccine
- FDA label
- Download (363 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention Bacillus Anthracis (Anthrax) 1 4 Completed Prevention Healthy Volunteers 1 3 Completed Prevention Anthrax 1 3 Completed Treatment Anthrax 1 2 Completed Prevention Anthrax 3 2 Completed Treatment Anthrax 1 2 Terminated Prevention Bacillus Anthracis (Anthrax) 1 1 Active Not Recruiting Prevention Anthrax 1 1 Active Not Recruiting Prevention Healthy Volunteers 1 1 Completed Prevention Anthrax 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, suspension Intramuscular; Subcutaneous Injection, suspension Intramuscular; Subcutaneous 100 ug/1mL Suspension Intramuscular; Subcutaneous 50 mcg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on December 01, 2015 20:05 / Updated on June 12, 2020 17:42